Alvotech, Teva secure FDA approval for Stelara biosimilar Selarsdi
Manufactured by Alvotech, Selarsdi is the second biosimilar approved under the strategic partnership between Alvotech and Teva, for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Apr 24
Manufactured by Alvotech, Selarsdi is the second biosimilar approved under the strategic partnership between Alvotech and Teva, for…
17 Apr 24
Medincell and AbbVie will co-develop up to six LAI therapeutic products whereas AbbVie will provide funding, manage the…
17 Apr 24
Leveraging ProPhase Labs’ AI platform, massive genomics database and patented esophageal cancer insights for Antibody Drug Conjugates development
15 Apr 24
In the Phase 3 study, Columvi plus chemotherapy showed a statistically significant improvement in overall survival (OS), progression-free…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Apr 24
The German drug maker will also get an exclusive global license to develop, manufacture and market the resulting…
04 Apr 24
The approval for Zevtera was based on the clinical efficacy and safety data from the Phase 3 ERADICATE…
02 Apr 24
STRO-003, which is currently in the final stages of pre-clinical development, targets the ROR1 tumour antigen, which is…
Patient CarePharmaceuticals and MedicinesPartnerships and Licensing Agreements
29 Mar 24
XTX301, which is a tumour-activated IL-12 designed to accelerate anti-tumour immunity, is currently being evaluated for its safety…
28 Mar 24
The approval is supported by the safety and efficacy data from the INNO2VATE programme and post-marketing safety data…
27 Mar 24
The FDA approval, following the US FDA Breakthrough Therapy Designation, is based on the results from the Phase…